From: Ovarian cancer: epigenetics, drug resistance, and progression
LncRNA | Adjust | Resistance against | Function | Target/pathway |
---|---|---|---|---|
HOTAIR | ↑ | Cisplatin | Correlates with DNA damage response and senescence | NF-κB [70]; HOXA7 [146]; miR-200c [147]; P65, caspase 3/9 [148]; MMP9, MMP3, E-cadherin, vimentin, snail [69]; Wnt/β-catenin [149]; |
H19 | ↑ | Cisplatin | Promotion of cell migration and invasion | IGF2 [79]; EZH2, P21, PTEN [150]; miR-370-3p [151]; let-7 [80]; miR-370-3p-TGF-beta [151]; |
MALAT1 | ↑ | Cisplatin | Promotion of cell proliferation, migration, and invasion | Notch1 [76]; miR-200c [90]; PI3K/AKT pathway [77]; |
MEG3 | ↓ | Cisplatin | Tumor suppressor | EMT [152]; miR-214 [86]; |
UCA1 | ↑ | Paclitaxel Cisplatin | Apoptosis; drug effluent system | miR-143/FOSL2 pathway [153]; |
XIST | ↑ | Cisplatin | Promotion of cell proliferation, migration, and invasion | hsa-miR-214-3p [93]; |
BC200 | ↓ | Carboplatin | Tumor suppressor | Inhibited cell proliferation and increased the sensitivity of OC cells to carboplatin [154]; |
LSINCT5 | ↑ | Paclitaxel | Promotion of cell proliferation, migration, and invasion | CXCL12/CXCR4 [155]; |
DNM3OS | ↑ | Cisplatin | Promotion of cell proliferation, migration, and invasion | EMT [152]; |
NEAT1 | ↑ | Paclitaxel | Promotion of cell proliferation and metastasis Inhibition of apoptosis | miR-383-3p [95]; ZEB1 [81]; |
ANRIL | ↑ | Cisplatin | Promotion of cell proliferation and cell cycle progression | let-7a/HMGA2 [83]; |
GAS5 | ↓ | Platinum | Induction of apoptosis | cyclin D1, p21, APAF1 [85]; |